Trial Profile
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 24 Feb 2022 Status changed from active, no longer recruiting to discontinued.
- 15 Jul 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 13 May 2021 This trial has been completed in Germany, according to European Clinical Trials Database record.